Physician profile
Michael I Rose
NPI 1225097454
$3,903.12
in general payments reported to CMS, 2019-2025
21 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,184 · 2020: $270 · 2021: $398 · 2022: $431 · 2023: $364 · 2024: $119 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,361.47 | 2019-2022 | |
| Sientra, INC. | $380.25 | 2020-2021 | |
| Mentor Worldwide LLC | $289.89 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Abbvie INC. | $148.52 | 2023-2025 | Revolve, Alloderm, Natrelle Saline-Filled Breast Implants |
| Checkpoint Surgical, INC | $114.03 | 2022-2023 | Checkpoint Stimulators |
| Acell, INC. | $104.73 | 2020 | |
| Stryker Corporation | $100.00 | 2019 | |
| Tela Bio, INC. | $62.38 | 2022 | |
| Kerecis Limited | $50.63 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Integra Lifesciences Corporation | $47.93 | 2023-2024 | Integra, Durasorb Monofilament Mesh, Primatrix |
| Lifenet Health | $47.56 | 2023 | |
| Bioventus LLC | $36.18 | 2022 | |
| Acera Surgical, INC. | $33.59 | 2024 | Restrata Wound Matrix |
| Biotronik Nro, INC. | $28.85 | 2023 | Biotronik |
| Biocomposites INC | $18.66 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $16.97 | 2025 | Phasix Mesh |
| Motiva USA, LLC | $16.06 | 2025 | |
| Misonix INC | $16.06 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $14.82 | 2025 | |
| Axogen | $14.54 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$280,516.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.